On Monday, August 10, Integra Lifesciences IART will release its latest earnings report. Benzinga's outlook for Integra Lifesciences is included in the following report.
Earnings and Revenue
Integra Lifesciences EPS is expected to be around $0.1, according to sell-side analysts. Sales will likely be near $242.80 million. In the same quarter last year, Integra Lifesciences reported earnings per share of $0.73 on revenue of $383.64 million. If the company were to report in-line earnings when it publishes results Monday, earnings would be down 86.3%. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | 0.64 | 0.67 | 0.65 | 0.66 |
| EPS Actual | 0.48 | 0.68 | 0.68 | 0.73 |
| Revenue Estimate | 363.24 M | 397.50 M | 376.69 M | 373.29 M |
| Revenue Actual | 354.32 M | 395.13 M | 379.10 M | 383.64 M |
Stock Performance
Over the last 52-week period, shares are down 22.83%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
Don't be surprised to see the stock move on comments made during its conference call. Integra Lifesciences is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/84cqvbpf
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
